Zobrazeno 1 - 10
of 137
pro vyhledávání: '"Akito Nozaki"'
Autor:
Feiqian Wang, Kazushi Numata, Akihiro Funaoka, Takafumi Kumamoto, Kazuhisa Takeda, Makoto Chuma, Akito Nozaki, Litao Ruan, Shin Maeda
Publikováno v:
European Journal of Radiology Open, Vol 13, Iss , Pp 100587- (2024)
Purpose: To use Sonazoid contrast-enhanced ultrasound (S-CEUS) and Gadolinium-Ethoxybenzyl-Diethylenetriamine Penta-Acetic Acid magnetic-resonance imaging (EOB-MRI), exploring a non-invasive preoperative diagnostic strategy for microvascular invasion
Externí odkaz:
https://doaj.org/article/c46c205ceffa423aaaccc8677cb5b38c
Autor:
Tyng‐Yuan Jang, Po‐Cheng Liang, Dae Won Jun, Jang Han Jung, Hidenori Toyoda, Chih‐Wen Wang, Man‐Fung Yuen, Ka Shing Cheung, Satoshi Yasuda, Sung Eun Kim, Eileen L. Yoon, Jihyun An, Masaru Enomoto, Ritsuzo Kozuka, Makoto Chuma, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Masanori Atsukawa, Taeang Arai, Korenobu Hayama, Masatoshi Ishigami, Yong Kyun Cho, Eiichi Ogawa, Hyoung Su Kim, Jae‐Jun Shim, Haruki Uojima, Soung Won Jeong, Sang Bong Ahn, Koichi Takaguchi, Tomonori Senoh, Maria Buti, Elena Vargas‐Accarino, Hiroshi Abe, Hirokazu Takahashi, Kaori Inoue, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lun Yeh, Chia‐Yen Dai, Chung‐Feng Huang, Mindie H. Nguyen, Ming‐Lung Yu
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 40, Iss 2, Pp 188-197 (2024)
Abstract Elevated serum gamma‐glutamyl transferase (GGT) levels are associated with chronic hepatitis B (CHB)‐related hepatocellular carcinoma. However, their role in predicting mortality in patients with CHB treated with nucleotide/nucleoside an
Externí odkaz:
https://doaj.org/article/e34d44b81a6e43dbaa69ede33654fff2
Autor:
Kazuhito Kawata, Masanori Atsukawa, Kazuyoshi Ohta, Takeshi Chida, Hidenao Noritake, Taeang Arai, Katsuhiko Iwakiri, Satoshi Yasuda, Hidenori Toyoda, Tomomi Okubo, Atsushi Hiraoka, Tsunamasa Watanabe, Haruki Uojima, Akito Nozaki, Joji Tani, Asahiro Morishita, Fujito Kageyama, Yuzo Sasada, Masamichi Nagasawa, Masahiro Matsushita, Tatsuki Oyaizu, Shigeru Mikami, Tadashi Ikegami, Hiroshi Abe, Kentaro Matsuura, Yasuhito Tanaka, Akihito Tsubota
Publikováno v:
Hepatology Communications, Vol 6, Iss 8, Pp 1855-1869 (2022)
Abstract Despite reports of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection after achieving sustained virological response (SVR), only few studies have demonstrated the incidence of other (non‐HCC) malignan
Externí odkaz:
https://doaj.org/article/d76ea7c332bc46b8b68c30a249551641
Autor:
Atsushi Kawamura, Haruki Uojima, Makoto Chuma, Xue Shao, Hisashi Hidaka, Takahide Nakazawa, Akira Take, Yoshihiko Sakaguchi, Kazushi Numata, Makoto Kako, Akito Nozaki, Shintaro Azuma, Kazue Horio, Chika Kusano, Koichiro Atsuda
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Lenvatinib is appropriate for reducing the production of nitric oxide (NO) and facilitating as block angiogenesis. However, to our knowledge, there are no data that support the correlation between NO and clinical response in patie
Externí odkaz:
https://doaj.org/article/a3db878031ea47dc9a5602705cc07dcf
Autor:
Xiaoping He, Yohko Hikiba, Yoshimasa Suzuki, Yoshinori Nakamori, Yushi Kanemaru, Makoto Sugimori, Takeshi Sato, Akito Nozaki, Makoto Chuma, Shin Maeda
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. Lenvatinib is approved as a first-line treatment for unresectable HCC. The therapeutic duration of lenvatinib is limited by resistance, but the underlying m
Externí odkaz:
https://doaj.org/article/c0127f48b27847648095dd1f0a306360
Autor:
Hidenori Toyoda, Masanori Atsukawa, Haruki Uojima, Akito Nozaki, Koichi Takaguchi, Atsushi Hiraoka, Ei Itobayashi, Tsunamasa Watanabe, Kentaro Matsuura, Noritomo Shimada, Hiroshi Abe, Kunihiko Tsuji, Norio Itokawa, Shigeru Mikami, Toru Ishikawa, Tsunekazu Oikawa, Satoshi Yasuda, Makoto Chuma, Akemi Tsutsui, Hiroki Ikeda, Taeang Arai, Akihito Tsubota, Takashi Kumada, Yasuhito Tanaka, Junko Tanaka
Publikováno v:
Gastro Hep Advances, Vol 1, Iss 4, Pp 508-515 (2022)
Backgrounds and Aims: Cirrhosis and hepatocellular carcinoma (HCC) are potentially fatal complications of chronic hepatitis C virus (HCV) infection. We investigated how compensated cirrhosis and a history of curatively treated HCC influenced patient
Externí odkaz:
https://doaj.org/article/258fcefe4bd94b20b8e7f9ba9a6e79fa
Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response
Autor:
Hidenori Toyoda, Atsushi Hiraoka, Haruki Uojima, Akito Nozaki, Noritomo Shimada, Koichi Takaguchi, Hiroshi Abe, Masanori Atsukawa, Kentaro Matsuura, Toru Ishikawa, Shigeru Mikami, Tsunamasa Watanabe, Ei Itobayashi, Kunihiko Tsuji, Taeang Arai, Satoshi Yasuda, Makoto Chuma, Tomonori Senoh, Akemi Tsutsui, Tomomi Okubo, Takuya Ehira, Takashi Kumada, Junko Tanaka
Publikováno v:
Hepatology Communications, Vol 5, Iss 7, Pp 1290-1299 (2021)
Hepatocellular carcinoma (HCC) can de novo develop in patients with chronic hepatitis C even after the achievement of sustained virologic response (SVR). We characterized de novo HCC after SVR, comparing it with HCC that developed in patients during
Externí odkaz:
https://doaj.org/article/9dc68ef7a8a04b45ab0ab152ac3846cf
Publikováno v:
Case Reports in Gastroenterology, Vol 15, Iss 1, Pp 436-442 (2021)
Oral direct-acting antivirals (DAAs) are the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Moreover, many DAAs include an indication for compensated liver cirrhosis. However, patients with decompensated HCV-associated ci
Externí odkaz:
https://doaj.org/article/fc2b5fcec605464c88ee252b4d015628
Autor:
Norio Itokawa, Masanori Atsukawa, Akihito Tsubota, Koichi Takaguchi, Makoto Nakamuta, Atsushi Hiraoka, Keizo Kato, Hiroshi Abe, Shigeru Mikami, Noritomo Shimada, Makoto Chuma, Akito Nozaki, Haruki Uojima, Chikara Ogawa, Toru Asano, Joji Tani, Asahiro Morishita, Tomonori Senoh, Naoki Yamashita, Tsunekazu Oikawa, Yoshihiro Matsumoto, Mai Koeda, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Taeang Arai, Korenobu Hayama, Ai‐Nakagawa Iwashita, Chisa Kondo, Toshifumi Tada, Hidenori Toyoda, Takashi Kumada, Katsuhiko Iwakiri
Publikováno v:
JGH Open, Vol 5, Iss 1, Pp 34-40 (2021)
Abstract Background and Aim Although tenofovir alafenamide (TAF), as well as entecavir (ETV), is widely used as first‐line treatment for patients with chronic hepatitis B, there are only a few studies comparing sequential therapy from ETV to TAF an
Externí odkaz:
https://doaj.org/article/05c3ed5d3b1f4d0b91e90401dec04abd
Autor:
Feiqian Wang, Kazushi Numata, Satoshi Komiyama, Haruo Miwa, Kazuya Sugimori, Katsuaki Ogushi, Satoshi Moriya, Akito Nozaki, Makoto Chuma, Litao Ruan, Shin Maeda
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundThe present study aimed to evaluate the efficacy and safety of combined lenvatinib (first-line systemic therapy) and radiofrequency ablation (RFA) therapy in patients with intermediate-stage hepatocellular carcinoma with beyond up-to-seven
Externí odkaz:
https://doaj.org/article/38c43d297a9347a3bdfaee7085949dcb